<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36738380</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>24</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-7284</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>European journal of epidemiology</Title><ISOAbbreviation>Eur J Epidemiol</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2 elicits non-sterilizing immunity and evades vaccine-induced immunity: implications for future vaccination strategies.</ArticleTitle><Pagination><StartPage>237</StartPage><EndPage>242</EndPage><MedlinePgn>237-242</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10654-023-00965-x</ELocationID><Abstract><AbstractText>Neither vaccination nor natural infection result in long-lasting protection against SARS-COV-2 infection and transmission, but both reduce the risk of severe COVID-19. To generate insights into optimal vaccination strategies for prevention of severe COVID-19 in the population, we extended a Susceptible-Exposed-Infectious-Removed (SEIR) mathematical model to compare the impact of vaccines that are highly protective against severe COVID-19 but not against infection and transmission, with those that block SARS-CoV-2 infection. Our analysis shows that vaccination strategies focusing on the prevention of severe COVID-19 are more effective than those focusing on creating of herd immunity. Key uncertainties that would affect the choice of vaccination strategies are: (1) the duration of protection against severe disease, (2) the protection against severe disease from variants that escape vaccine-induced immunity, (3) the incidence of long-COVID and level of protection provided by the vaccine, and (4) the rate of serious adverse events following vaccination, stratified by demographic variables.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Beukenhorst</LastName><ForeName>Anna L</ForeName><Initials>AL</Initials><Identifier Source="ORCID">0000-0002-1765-4890</Identifier><AffiliationInfo><Affiliation>Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA. anna.beukenhorst@leydenlabs.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK. anna.beukenhorst@leydenlabs.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leyden Laboratories BV, Amsterdam, The Netherlands. anna.beukenhorst@leydenlabs.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Koch</LastName><ForeName>Clarissa M</ForeName><Initials>CM</Initials><Identifier Source="ORCID">0000-0002-7424-6009</Identifier><AffiliationInfo><Affiliation>Leyden Laboratories BV, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hadjichrysanthou</LastName><ForeName>Christoforos</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-6166-5899</Identifier><AffiliationInfo><Affiliation>Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alter</LastName><ForeName>Galit</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Ragon Institute of MGH MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Wolf</LastName><ForeName>Frank</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-6264-2461</Identifier><AffiliationInfo><Affiliation>Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Roy M</ForeName><Initials>RM</Initials><Identifier Source="ORCID">0000-0002-9528-3175</Identifier><AffiliationInfo><Affiliation>Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goudsmit</LastName><ForeName>Jaap</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Leyden Laboratories BV, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Epidemiology, Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Eur J Epidemiol</MedlineTA><NlmUniqueID>8508062</NlmUniqueID><ISSNLinking>0393-2990</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014612">Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014612" MajorTopicYN="Y">Vaccines</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Control measures</Keyword><Keyword MajorTopicYN="N">Coronavirus</Keyword><Keyword MajorTopicYN="N">Herd immunity</Keyword><Keyword MajorTopicYN="N">Immunology</Keyword><Keyword MajorTopicYN="N">Infection</Keyword><Keyword MajorTopicYN="N">Influenza</Keyword><Keyword MajorTopicYN="N">Population&#xa0;modelling</Keyword><Keyword MajorTopicYN="N">Respiratory infections</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2&#xa0;pandemic</Keyword><Keyword MajorTopicYN="N">Vaccine effectiveness</Keyword><Keyword MajorTopicYN="N">Vaccines</Keyword></KeywordList><CoiStatement>C.H., R.M.A. and F.d.W. have no relevant financial or non-financial interests to disclose. A.B.,&#xa0;C.K., G.A. and J.G. have disclosed that they are employees of Leyden Laboratories with stock&#xa0;options in this company. Leyden Laboratories develops intranasal technologies to administer substances for prevention and treatment of respiratory infections and non-communicable diseases, and is currently not involved in vaccine development, production or distribution.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>4</Day><Hour>11</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36738380</ArticleId><ArticleId IdType="pmc">PMC9898703</ArticleId><ArticleId IdType="doi">10.1007/s10654-023-00965-x</ArticleId><ArticleId IdType="pii">10.1007/s10654-023-00965-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anderson RM, et al. The SARS-CoV-2 pandemic: remaining uncertainties in our understanding of the epidemiology and transmission dynamics of the virus, and challenges to be overcome. Interface Focus. 2021;11(6):20210008. doi: 10.1098/rsfs.2021.0008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsfs.2021.0008</ArticleId><ArticleId IdType="pmc">PMC8504893</ArticleId><ArticleId IdType="pubmed">34956588</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullin S, van der Wyk B, Asher JL, Compton SR, Allore HG, Zeiss CJ. Modeling pandemic to endemic patterns of SARS-CoV-2 transmission using parameters estimated from animal model data. PNAS Nexus. 2022;1(3):pgac096. doi: 10.1093/pnasnexus/pgac096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/pnasnexus/pgac096</ArticleId><ArticleId IdType="pmc">PMC9254158</ArticleId><ArticleId IdType="pubmed">35799833</ArticleId></ArticleIdList></Reference><Reference><Citation>Barouch DH. Covid-19 vaccines&#x2014;immunity, variants, boosters. N Engl J Med. 2022;387(11):1011&#x2013;1020. doi: 10.1056/NEJMra2206573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra2206573</ArticleId><ArticleId IdType="pmc">PMC9454645</ArticleId><ArticleId IdType="pubmed">36044620</ArticleId></ArticleIdList></Reference><Reference><Citation>Singanayagam A, et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. Lancet Infect Dis. 2022;22(2):183&#x2013;195. doi: 10.1016/S1473-3099(21)00648-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00648-4</ArticleId><ArticleId IdType="pmc">PMC8554486</ArticleId><ArticleId IdType="pubmed">34756186</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen H, et al. Comparative transmission of SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) variants and the impact of vaccination: national cohort study, England. MedRxiv. 2022 doi: 10.1101/2022.02.15.22271001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.02.15.22271001</ArticleId><ArticleId IdType="pmc">PMC10125873</ArticleId><ArticleId IdType="pubmed">36938806</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheward, Daniel J., et al. &#x201c;Evasion of neutralising antibodies by omicron sublineage BA. 2.75.&#x201d; The Lancet Infectious Diseases 22.10 (2022): 1421&#x2013;1422. 10.1016/S1473-3099(22)00524-2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9436366</ArticleId><ArticleId IdType="pubmed">36058228</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature. 2022 doi: 10.1038/s41586-022-05644-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05644-7</ArticleId><ArticleId IdType="pmc">PMC9931576</ArticleId><ArticleId IdType="pubmed">36535326</ArticleId></ArticleIdList></Reference><Reference><Citation>Altarawneh HN, et al. Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants. N Engl J Med. 2022;387:1620&#x2013;2. doi: 10.1056/NEJMc2209306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2209306</ArticleId><ArticleId IdType="pmc">PMC9559315</ArticleId><ArticleId IdType="pubmed">36198139</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal U, et al. Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales. The Lancet. 2022;400(10360):1305&#x2013;1320. doi: 10.1016/S0140-6736(22)01656-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01656-7</ArticleId><ArticleId IdType="pmc">PMC9560746</ArticleId><ArticleId IdType="pubmed">36244382</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheutlin Amanda, et al. Durability of Protection Post&#x2013;Primary COVID-19 Vaccination in the United States.
Vaccines 10.9 (2022): 1458. https://www.mdpi.com/2076-393X/10/9/1458</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9505933</ArticleId><ArticleId IdType="pubmed">36146536</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Raddad LJ, Chemaitelly H, Bertollini R. Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar. N Engl J Med. 2022;386(11):1091&#x2013;1093. doi: 10.1056/NEJMc2119432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2119432</ArticleId><ArticleId IdType="pmc">PMC8809505</ArticleId><ArticleId IdType="pubmed">35081294</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H, et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. N Engl J Med. 2021;385(24):e83. doi: 10.1056/NEJMoa2114114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2114114</ArticleId><ArticleId IdType="pmc">PMC8522799</ArticleId><ArticleId IdType="pubmed">34614327</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg Y, et al. Waning immunity after the BNT162b2 vaccine in Israel. N Engl J Med. 2021;385:e85. doi: 10.1056/NEJMoa2114228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2114228</ArticleId><ArticleId IdType="pmc">PMC8609604</ArticleId><ArticleId IdType="pubmed">34706170</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokal A, et al. Analysis of mRNA vaccination-elicited RBD-specific memory B cells reveals strong but incomplete immune escape of the SARS-CoV-2 Omicron variant. Immun Apr. 2022 doi: 10.1016/j.immuni.2022.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2022.04.002</ArticleId><ArticleId IdType="pmc">PMC8986479</ArticleId><ArticleId IdType="pubmed">35483354</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarke A, et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell. 2022;185(5):847&#x2013;859.e11. doi: 10.1016/j.cell.2022.01.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.015</ArticleId><ArticleId IdType="pmc">PMC8784649</ArticleId><ArticleId IdType="pubmed">35139340</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng B, et al. Altered TMPRSS2 usage by SARS-CoV-2 omicron impacts infectivity and fusogenicity. Nature. 2022;603(7902):706&#x2013;14. doi: 10.1038/s41586-022-04474-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04474-x</ArticleId><ArticleId IdType="pmc">PMC8942856</ArticleId><ArticleId IdType="pubmed">35104837</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahan K, et al. Reduced pathogenicity of the SARS-CoV-2 omicron variant in hamsters. Med. 2022;3(4):262&#x2013;268.e4. doi: 10.1016/j.medj.2022.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2022.03.004</ArticleId><ArticleId IdType="pmc">PMC8926874</ArticleId><ArticleId IdType="pubmed">35313451</ArticleId></ArticleIdList></Reference><Reference><Citation>Armando F, et al. SARS-CoV-2 Omicron variant causes mild pathology in the upper and lower respiratory tract of hamsters. Nat Commun. 2022;13(1):3519. doi: 10.1038/s41467-022-31200-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-31200-y</ArticleId><ArticleId IdType="pmc">PMC9207884</ArticleId><ArticleId IdType="pubmed">35725735</ArticleId></ArticleIdList></Reference><Reference><Citation>Bager P, et al. Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study. Lancet Infect Dis. 2022;22:967&#x2013;76. doi: 10.1016/S1473-3099(22)00154-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00154-2</ArticleId><ArticleId IdType="pmc">PMC9033212</ArticleId><ArticleId IdType="pubmed">35468331</ArticleId></ArticleIdList></Reference><Reference><Citation>Veneti L, et al. Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022. Eurosurveillance. 2022 doi: 10.2807/1560-7917.ES.2022.27.4.2200077.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2022.27.4.2200077</ArticleId><ArticleId IdType="pmc">PMC8796289</ArticleId><ArticleId IdType="pubmed">35086614</ArticleId></ArticleIdList></Reference><Reference><Citation>Altarawneh HN, et al. Effects of previous infection and vaccination on symptomatic omicron infections. N Engl J Med. 2022 doi: 10.1056/NEJMoa2203965.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2203965</ArticleId><ArticleId IdType="pmc">PMC9258753</ArticleId><ArticleId IdType="pubmed">35704396</ArticleId></ArticleIdList></Reference><Reference><Citation>Spicer KB, Glick C, Cavanaugh AM, Thoroughman D. Protective immunity after natural infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)&#x2013;Kentucky, USA, 2020. Int J Infect Dis. 2020;114:21&#x2013;28. doi: 10.1016/j.ijid.2021.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.10.010</ArticleId><ArticleId IdType="pmc">PMC8506664</ArticleId><ArticleId IdType="pubmed">34649001</ArticleId></ArticleIdList></Reference><Reference><Citation>Roskosky M, et al. Notes from the field:SARS-CoV-2 omicron variant infection in 10 persons within 90 days of previous SARS-CoV-2 delta variant infection&#x2014;Four States, October 2021&#x2013;January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(14):524&#x2013;526. doi: 10.15585/mmwr.mm7114a2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7114a2</ArticleId><ArticleId IdType="pmc">PMC8989372</ArticleId><ArticleId IdType="pubmed">35389976</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulliam JRC, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science (1979) 2022 doi: 10.1126/science.abn4947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abn4947</ArticleId><ArticleId IdType="pmc">PMC8995029</ArticleId><ArticleId IdType="pubmed">35289632</ArticleId></ArticleIdList></Reference><Reference><Citation>Edridge AWD, et al. Seasonal coronavirus protective immunity is short-lasting. Nat Med. 2020;26(11):1691&#x2013;1693. doi: 10.1038/s41591-020-1083-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1083-1</ArticleId><ArticleId IdType="pubmed">32929268</ArticleId></ArticleIdList></Reference><Reference><Citation>Mwita Morobe J, et al. Trends and Intensity of Rhinovirus Invasions in Kilifi, Coastal Kenya, Over a 12-Year Period, 2007&#x2013;2018. Open Forum Infect Dis. 2021;8(12):ofab571. doi: 10.1093/ofid/ofab571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab571</ArticleId><ArticleId IdType="pmc">PMC8694214</ArticleId><ArticleId IdType="pubmed">34988244</ArticleId></ArticleIdList></Reference><Reference><Citation>Mykytyn AZ, et al. Antigenic cartography of SARS-CoV-2 reveals that Omicron BA. 1 and BA. 2 are antigenically distinct. Science Immunology. 2022 doi: 10.1126/sciimmunol.abq4450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abq4450</ArticleId><ArticleId IdType="pmc">PMC9273038</ArticleId><ArticleId IdType="pubmed">35737747</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S, Karuppanan K, Subramaniam G. Omicron. (BA.1) and sub-variants (BA.1, BA.2 and BA.3) of SARS-CoV-2 spike infectivity and pathogenicity: a comparative sequence and structural-based computational assessment. J Med Virol. 2022 doi: 10.1101/2022.02.11.480029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.02.11.480029</ArticleId><ArticleId IdType="pmc">PMC9347785</ArticleId><ArticleId IdType="pubmed">35680610</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Valtanen P, et al. SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents. Cell Rep Med. 2022;3(6):100651. doi: 10.1016/j.xcrm.2022.100651.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100651</ArticleId><ArticleId IdType="pmc">PMC9110310</ArticleId><ArticleId IdType="pubmed">35654046</ArticleId></ArticleIdList></Reference><Reference><Citation>Arora P, et al. SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies. Cell Host Microbe. 2022 doi: 10.1016/j.chom.2022.04.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2022.04.017</ArticleId><ArticleId IdType="pmc">PMC9072809</ArticleId><ArticleId IdType="pubmed">35588741</ArticleId></ArticleIdList></Reference><Reference><Citation>Iketani S, et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature. 2022;604(7906):553&#x2013;6. doi: 10.1038/s41586-022-04594-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04594-4</ArticleId><ArticleId IdType="pmc">PMC9021018</ArticleId><ArticleId IdType="pubmed">35240676</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou H, Dcosta BM, Landau NR, Tada T. Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 variants to vaccine-elicited sera and therapeutic monoclonal antibodies. Viruses. 2022;14(6):1334. doi: 10.3390/v14061334.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14061334</ArticleId><ArticleId IdType="pmc">PMC9228817</ArticleId><ArticleId IdType="pubmed">35746806</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, and BA.5. Nature. 2022 doi: 10.1038/s41586-022-05053-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05053-w</ArticleId><ArticleId IdType="pmc">PMC9385487</ArticleId><ArticleId IdType="pubmed">35790190</ArticleId></ArticleIdList></Reference><Reference><Citation>Quandt J, et al. Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes. Sci Immunol. 2022 doi: 10.1126/sciimmunol.abq2427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abq2427</ArticleId><ArticleId IdType="pmc">PMC9162083</ArticleId><ArticleId IdType="pubmed">35653438</ArticleId></ArticleIdList></Reference><Reference><Citation>Alter G, et al. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. Nature. 2021;596(7871):268&#x2013;72. doi: 10.1038/s41586-021-03681-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03681-2</ArticleId><ArticleId IdType="pmc">PMC8357629</ArticleId><ArticleId IdType="pubmed">34107529</ArticleId></ArticleIdList></Reference><Reference><Citation>Arora P, et al. Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5. Lancet Infect Dis. 2022;22(8):1117&#x2013;1118. doi: 10.1016/S1473-3099(22)00422-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00422-4</ArticleId><ArticleId IdType="pmc">PMC9239574</ArticleId><ArticleId IdType="pubmed">35777385</ArticleId></ArticleIdList></Reference><Reference><Citation>Cele S, et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature. 2022;602(7898):654&#x2013;6. doi: 10.1038/s41586-021-04387-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04387-1</ArticleId><ArticleId IdType="pmc">PMC8866126</ArticleId><ArticleId IdType="pubmed">35016196</ArticleId></ArticleIdList></Reference><Reference><Citation>Hachmann NP, et al. Neutralization escape by SARS-CoV-2 omicron subvariants BA.2.12.1, BA.4, and BA.5. N Engl J Med. 2022 doi: 10.1056/NEJMc2206576.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2206576</ArticleId><ArticleId IdType="pmc">PMC9258748</ArticleId><ArticleId IdType="pubmed">35731894</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassauni&#xe8;re R, et al. Neutralizing antibodies against the SARS-CoV-2 omicron variant (BA.1) 1 to 18 weeks after the second and third doses of the BNT162b2 mRNA vaccine. JAMA Netw Open. 2022;5(5):e2212073. doi: 10.1001/jamanetworkopen.2022.12073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.12073</ArticleId><ArticleId IdType="pmc">PMC9107029</ArticleId><ArticleId IdType="pubmed">35560054</ArticleId></ArticleIdList></Reference><Reference><Citation>van Gils MJ, et al. Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: a prospective cohort study. PLoS Med. 2022;19(5):e1003991. doi: 10.1371/journal.pmed.1003991.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003991</ArticleId><ArticleId IdType="pmc">PMC9113667</ArticleId><ArticleId IdType="pubmed">35580156</ArticleId></ArticleIdList></Reference><Reference><Citation>Medi&#x107; S, et al. Risk and severity of SARS-CoV-2 reinfections during 2020&#x2013;2022 in Vojvodina, Serbia: a population-level observational study. Lancet Reg Health Eur. 2022;20:100453. doi: 10.1016/j.lanepe.2022.100453.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2022.100453</ArticleId><ArticleId IdType="pmc">PMC9246704</ArticleId><ArticleId IdType="pubmed">35791336</ArticleId></ArticleIdList></Reference><Reference><Citation>Yahav D, et al. Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity. Clin Microbiol Infect. 2021;27(3):315&#x2013;8. doi: 10.1016/j.cmi.2020.11.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.11.028</ArticleId><ArticleId IdType="pmc">PMC7718119</ArticleId><ArticleId IdType="pubmed">33285276</ArticleId></ArticleIdList></Reference><Reference><Citation>Michlmayr D, et al. Observed protection against SARS-CoV-2 reinfection following a primary infection: a Danish cohort study among unvaccinated using two years of nationwide PCR-test data. Lancet Reg Health Eur. 2022;20:100452. doi: 10.1016/j.lanepe.2022.100452.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2022.100452</ArticleId><ArticleId IdType="pmc">PMC9245510</ArticleId><ArticleId IdType="pubmed">35791335</ArticleId></ArticleIdList></Reference><Reference><Citation>Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science (1979) 2020;368(6493):860&#x2013;868. doi: 10.1126/science.abb5793.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb5793</ArticleId><ArticleId IdType="pmc">PMC7164482</ArticleId><ArticleId IdType="pubmed">32291278</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson RM, May RM. Infectious diseases of humans: dynamics and control. Oxford University Press; 1992.</Citation></Reference><Reference><Citation>Anderson RM, May RM. Vaccination and herd immunity to infectious diseases. Nature. 1985;318(6044):323&#x2013;329. doi: 10.1038/318323a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/318323a0</ArticleId><ArticleId IdType="pubmed">3906406</ArticleId></ArticleIdList></Reference><Reference><Citation>Feikin DR, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. The Lancet. 2022;399(10328):924&#x2013;944. doi: 10.1016/S0140-6736(22)00152-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00152-0</ArticleId><ArticleId IdType="pmc">PMC8863502</ArticleId><ArticleId IdType="pubmed">35202601</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson RM, Vegvari C, Truscott J, Collyer BS. Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination. The Lancet. 2020;396(10263):1614&#x2013;1616. doi: 10.1016/S0140-6736(20)32318-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32318-7</ArticleId><ArticleId IdType="pmc">PMC7836302</ArticleId><ArticleId IdType="pubmed">33159850</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker PGT, et al. The impact of COVID-19 and strategies for mitigation and suppression in low- and middle-income countries. Science (1979) 2020;369(6502):413&#x2013;422. doi: 10.1126/science.abc0035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc0035</ArticleId><ArticleId IdType="pmc">PMC7292504</ArticleId><ArticleId IdType="pubmed">32532802</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjichrysanthou C, et al. Exploring the role of antiviral nasal sprays in the control of emerging respiratory infections in the community. Infect Dis Ther. 2022;11(6):2287&#x2013;2296. doi: 10.1007/s40121-022-00710-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-022-00710-z</ArticleId><ArticleId IdType="pmc">PMC9618272</ArticleId><ArticleId IdType="pubmed">36309921</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly SL, le Rutte EA, Richter M, Penny MA, Shattock AJ. COVID-19 vaccine booster strategies in light of emerging viral variants: frequency, timing, and target groups. Infect Dis Ther. 2022 doi: 10.1007/s40121-022-00683-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-022-00683-z</ArticleId><ArticleId IdType="pmc">PMC9464609</ArticleId><ArticleId IdType="pubmed">36094720</ArticleId></ArticleIdList></Reference><Reference><Citation>Knock ES, et al. Key epidemiological drivers and impact of interventions in the 2020 SARS-CoV-2 epidemic in Englan. Sci Transl Med. 2021 doi: 10.1126/scitranslmed.abg4262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abg4262</ArticleId><ArticleId IdType="pmc">PMC8432953</ArticleId><ArticleId IdType="pubmed">34158411</ArticleId></ArticleIdList></Reference><Reference><Citation>Backer JA, Wallinga J, Meijer A, Donker GA, van der Hoek W, van Boven M. The impact of influenza vaccination on infection, hospitalisation and mortality in the Netherlands between 2003 and 2015. Epidemics. 2019;26:77&#x2013;85. doi: 10.1016/j.epidem.2018.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.epidem.2018.10.001</ArticleId><ArticleId IdType="pubmed">30344024</ArticleId></ArticleIdList></Reference><Reference><Citation>Biggerstaff M, Cauchemez S, Reed C, Gambhir M, Finelli L. Estimates of the reproduction number for seasonal, pandemic, and zoonotic influenza: a systematic review of the literature. BMC Infect Dis. 2014;14(1):480. doi: 10.1186/1471-2334-14-480.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-14-480</ArticleId><ArticleId IdType="pmc">PMC4169819</ArticleId><ArticleId IdType="pubmed">25186370</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann P, Pittet LF, Curtis N. How common is long COVID in children and adolescents? Pediatr Infect Dis J. 2021;40(12):e482&#x2013;e487. doi: 10.1097/INF.0000000000003328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000003328</ArticleId><ArticleId IdType="pmc">PMC8575095</ArticleId><ArticleId IdType="pubmed">34870392</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H, Raza S, Nowell J, Young M, Edison P. Long covid&#x2014;mechanisms, risk factors, and management. BMJ. 2021 doi: 10.1136/bmj.n1648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Brito AF, et al. Global disparities in SARS-CoV-2 genomic surveillance. Nat Commun. 2022;13(1):7003. doi: 10.1038/s41467-022-33713-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-33713-y</ArticleId><ArticleId IdType="pmc">PMC9667854</ArticleId><ArticleId IdType="pubmed">36385137</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis, Hannah E., et al. &#x201c;Long COVID: major findings, mechanisms and recommendations.&#x201d; Nature Reviews Microbiology (2023): 1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson RM, May RM. Coevolution of hosts and parasites. Parasitology. 1982;85(2):411&#x2013;426. doi: 10.1017/S0031182000055360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0031182000055360</ArticleId><ArticleId IdType="pubmed">6755367</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>